Under this pilot, the EMA not only sits in judgment of companies’ applications for drug approval, but it is also being asked to assist these companies in navigating the bureaucratic process of application, in designing the protocol for testing the drugs, and even in identifying which kinds of drugs should be developed. As traditional testing methods become increasingly unsuitable for these lucrative classes of drugs, governments have charged their regulatory agencies with figuring out ways to assist biomedical and other pharmaceutical companies bring these products to market.